Concepció Marin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Concepció Marin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
E. Aguilar
Laboratori de Neurologia Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
10 shared publications- Guadalupe Mengod
IIBB-CSIC, IDIBAPS, CIBERNED, Barcelona, Spain
8 shared publications M. Bonastre
INGENIO, IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
8 shared publications- Roser Cortés
Departament de Neuroquímica, Institut d'Investigacions Biomèdiques de Barcelona, CSIC‐IDIBAPS, Barcelona, Spain
8 shared publications - Maria Cruz Rodriguez-Oroz
Department of Neurology Clínica Universidad de Navarra Pamplona Spain
5 shared publications J.A. Obeso
Department of Neurology and Neuroscience Area, Clínica Universitaria and Medical School, CIMA, University of Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
4 shared publications
Latest Publications
- 1 October 2015
- Published by Elsevier in Neuropharmacology
- Vol. 97, 365-375
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms
- 1 October 2015
- Published by Elsevier in Neuropharmacology
- Vol. 97, 365-375
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms
- 1 September 2015
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 56, 294-314
Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches
- 1 September 2015
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 56, 294-314
Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches
- 1 April 2014
- Published by Elsevier in Neurobiology of Disease
- Vol. 64, 36-47
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats
- 1 April 2014
- Published by Elsevier in Neurobiology of Disease
- Vol. 64, 36-47
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats
- 1 December 2013
- Published by Elsevier in Experimental Neurology
- Vol. 250, 304-312
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease
- 1 December 2013
- Published by Elsevier in Experimental Neurology
- Vol. 250, 304-312
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease
The metabotropic glutamate receptor antagonist 2‐methyl‐6‐(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L‐dopa‐induced dyskinesias
The striatal glutamatergic hyperactivity is considered critical in the development of levodopa‐induced dyskinesias (LID) in Parkinson's disease (PD). Pharmacological antagonism of the metabotropic glutamate receptors (mGluRs), in particular, the subtype mGluR5, can inhibit the expression of dyskinesia in both rodent and nonhuman primate models of PD. However, the exact mechanisms underlying the mGluR5 antagonism effects are not completely known. The vesicular glutamate transporters (VGluts) are localized in the synaptic vesicles of the striatal glutamatergic axonal terminals. The effects of mGluR5 antagonism modulating VGlut1 and VGlut2, as selective markers for the corticostriatal and thalamostriatal pathways, respectively, are still unknown. We investigated the effects of the mGluR5 antagonist, 2‐methyl‐6‐(phenylethynyl) pyridine (MPEP) on the striatal expression of VGlut1 and VGlut2 in levodopa‐treated hemiparkinsonian rats. Male Sprague–Dawley rats received a unilateral 6‐hydroxydopamine (6‐OHDA) administration in the nigrostriatal pathway. Rats were treated with: (a) levodopa (12 mg/kg/day with benserazide 15 mg/kg, ip) + vehicle; (b) MPEP (1.5 mg/kg/day, ip) + vehicle; (c) levodopa + MPEP, or (d) saline for 10 days. Levodopa treatment induced dyskinesias and did not modify the striatal expression of either VGlut1 or VGlut2. The administration of MPEP significantly attenuated LID and decreased the levels of VGlut2, but not the VGlut1, in the striatum ipsilateral to the lesion (P < 0.05). Our results suggest that the effects of MPEP on LID might be mediated by a modulating effect on VGlut 2 expression. Synapse, 2011.
The metabotropic glutamate receptor antagonist 2‐methyl‐6‐(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L‐dopa‐induced dyskinesias
The striatal glutamatergic hyperactivity is considered critical in the development of levodopa‐induced dyskinesias (LID) in Parkinson's disease (PD). Pharmacological antagonism of the metabotropic glutamate receptors (mGluRs), in particular, the subtype mGluR5, can inhibit the expression of dyskinesia in both rodent and nonhuman primate models of PD. However, the exact mechanisms underlying the mGluR5 antagonism effects are not completely known. The vesicular glutamate transporters (VGluts) are localized in the synaptic vesicles of the striatal glutamatergic axonal terminals. The effects of mGluR5 antagonism modulating VGlut1 and VGlut2, as selective markers for the corticostriatal and thalamostriatal pathways, respectively, are still unknown. We investigated the effects of the mGluR5 antagonist, 2‐methyl‐6‐(phenylethynyl) pyridine (MPEP) on the striatal expression of VGlut1 and VGlut2 in levodopa‐treated hemiparkinsonian rats. Male Sprague–Dawley rats received a unilateral 6‐hydroxydopamine (6‐OHDA) administration in the nigrostriatal pathway. Rats were treated with: (a) levodopa (12 mg/kg/day with benserazide 15 mg/kg, ip) + vehicle; (b) MPEP (1.5 mg/kg/day, ip) + vehicle; (c) levodopa + MPEP, or (d) saline for 10 days. Levodopa treatment induced dyskinesias and did not modify the striatal expression of either VGlut1 or VGlut2. The administration of MPEP significantly attenuated LID and decreased the levels of VGlut2, but not the VGlut1, in the striatum ipsilateral to the lesion (P < 0.05). Our results suggest that the effects of MPEP on LID might be mediated by a modulating effect on VGlut 2 expression. Synapse, 2011.
- 31 March 2011
- Published by Elsevier in Neurochemistry International
- Vol. 58 (4) , 521-526
In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression
- 31 March 2011
- Published by Elsevier in Neurochemistry International
- Vol. 58 (4) , 521-526
In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression
- 28 August 2009
- Published by Wiley in European Journal of Neuroscience
- Vol. 30 (5) , 823-832
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats
We investigated the effect of early vs. late initiation of levodopa treatment on dyskinetic movements, rotational behavior and molecular markers in hemiparkinsonian rats. Male Sprague‐Dawley rats received a unilateral 6‐hydroxydopamine (6‐OHDA) administration in the nigrostriatal pathway. Rats were divided into three groups treated with: (i) levodopa (6 mg/kg) twice daily for 22 days starting at 4 weeks after 6‐OHDA (Early group); (ii) levodopa at the same dose, regimen and duration but starting at 12 weeks after 6‐OHDA (Late group), and (iii) saline starting at 4 weeks after 6‐OHDA and continuing until the Late group finished treatment. Dyskinesias were quantified on days 1 and 22 of levodopa treatment. Striatal expression of preproenkephalin and preprodynorphin mRNAs, subthalamic cytochrome oxidase mRNA, and glutamate decarboxylase 67 mRNA in the pars reticulata of the substantia nigra was measured byin‐situhybridization. After 22 days of levodopa treatment, the percentage of rats showing dyskinesia was lower in the Early group than in the Late group (60% vs. 100%, respectively). No significant differences in total dyskinesia score were observed between both groups with the exception of the orolingual dyskinesias that were significantly less frequent in the Late group (P < 0.01). No significant differences were observed in the molecular markers between the Early and Late groups. Prompt initiation of levodopa treatment might be able to delay some of the basal ganglia molecular and circuitry changes underlying the development of dyskinesia but, once developed, they are behaviorally and molecularly similar to those appearing after late initiation of levodopa.
- 28 August 2009
- Published by Wiley in European Journal of Neuroscience
- Vol. 30 (5) , 823-832
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats
We investigated the effect of early vs. late initiation of levodopa treatment on dyskinetic movements, rotational behavior and molecular markers in hemiparkinsonian rats. Male Sprague‐Dawley rats received a unilateral 6‐hydroxydopamine (6‐OHDA) administration in the nigrostriatal pathway. Rats were divided into three groups treated with: (i) levodopa (6 mg/kg) twice daily for 22 days starting at 4 weeks after 6‐OHDA (Early group); (ii) levodopa at the same dose, regimen and duration but starting at 12 weeks after 6‐OHDA (Late group), and (iii) saline starting at 4 weeks after 6‐OHDA and continuing until the Late group finished treatment. Dyskinesias were quantified on days 1 and 22 of levodopa treatment. Striatal expression of preproenkephalin and preprodynorphin mRNAs, subthalamic cytochrome oxidase mRNA, and glutamate decarboxylase 67 mRNA in the pars reticulata of the substantia nigra was measured byin‐situhybridization. After 22 days of levodopa treatment, the percentage of rats showing dyskinesia was lower in the Early group than in the Late group (60% vs. 100%, respectively). No significant differences in total dyskinesia score were observed between both groups with the exception of the orolingual dyskinesias that were significantly less frequent in the Late group (P < 0.01). No significant differences were observed in the molecular markers between the Early and Late groups. Prompt initiation of levodopa treatment might be able to delay some of the basal ganglia molecular and circuitry changes underlying the development of dyskinesia but, once developed, they are behaviorally and molecularly similar to those appearing after late initiation of levodopa.
- 28 July 2009
- Published by Springer Nature in Psychopharmacology
- Vol. 206 (2) , 233-242
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats
Rationale Striatal glutamatergic hyperactivity through the metabotropic receptors and their intracellular signaling pathways is considered critical in the development of levodopa-induced dyskinesias in Parkinson's disease and in experimental parkinsonism. Objective We investigated whether the administration of the metabotropic glutamate antagonist, MPEP, modifies striatal expression of Homer family proteins which are involved in the intracellular mechanisms mediated by these receptors. Materials and methods Sprague–Dawley rats were unilaterally lesioned in the nigrostriatal pathway with 6-hydroxydopamine (8 μg) and treated with: levodopa (12 mg/kg, i.p.) plus vehicle (n = 10) divided in two daily injections; levodopa plus MPEP (1.5 and 3 mg/kg, i.p.; n = 6–13) divided in two daily injections; or saline (n = 7) for 10 consecutive days. Axial, limb, and orolingual dyskinesias were evaluated. Striatal expression of tyrosine hydroxylase (TH), Homer 1a, 1b/c, and deltaFosB were measured by Western Blot. Results Animals treated with levodopa showed an increase of dyskinesia score (p < 0.01) that was attenuated by the administration of MPEP (p < 0.01). In the ipsilateral side of the lesion, striatal TH expression was decreased (p < 0.01). No significant differences in striatal Homer 1a or b/c expression were observed between the groups of treatment. Striatal deltaFosB expression increased in the animals treated with levodopa (p < 0.05) being attenuated after MPEP administration (p < 0.05). MPEP effect was not paralleled by any modification of striatal Homer proteins expression. Conclusions These results suggest that Homer protein family is not causally involved in the development of dyskinetic movements induced by levodopa treatment in this animal model of parkinsonism.
- 28 July 2009
- Published by Springer Nature in Psychopharmacology
- Vol. 206 (2) , 233-242
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats
Rationale Striatal glutamatergic hyperactivity through the metabotropic receptors and their intracellular signaling pathways is considered critical in the development of levodopa-induced dyskinesias in Parkinson's disease and in experimental parkinsonism. Objective We investigated whether the administration of the metabotropic glutamate antagonist, MPEP, modifies striatal expression of Homer family proteins which are involved in the intracellular mechanisms mediated by these receptors. Materials and methods Sprague–Dawley rats were unilaterally lesioned in the nigrostriatal pathway with 6-hydroxydopamine (8 μg) and treated with: levodopa (12 mg/kg, i.p.) plus vehicle (n = 10) divided in two daily injections; levodopa plus MPEP (1.5 and 3 mg/kg, i.p.; n = 6–13) divided in two daily injections; or saline (n = 7) for 10 consecutive days. Axial, limb, and orolingual dyskinesias were evaluated. Striatal expression of tyrosine hydroxylase (TH), Homer 1a, 1b/c, and deltaFosB were measured by Western Blot. Results Animals treated with levodopa showed an increase of dyskinesia score (p < 0.01) that was attenuated by the administration of MPEP (p < 0.01). In the ipsilateral side of the lesion, striatal TH expression was decreased (p < 0.01). No significant differences in striatal Homer 1a or b/c expression were observed between the groups of treatment. Striatal deltaFosB expression increased in the animals treated with levodopa (p < 0.05) being attenuated after MPEP administration (p < 0.05). MPEP effect was not paralleled by any modification of striatal Homer proteins expression. Conclusions These results suggest that Homer protein family is not causally involved in the development of dyskinetic movements induced by levodopa treatment in this animal model of parkinsonism.
- 22 January 2009
- Published by Springer Nature in Psychopharmacology
- Vol. 204 (2) , 241-250
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
Rationale Dyskinesia affects the majority of levodopa-treated parkinsonian patients within 5–10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the appearance of dyskinesias. It is thus conceivable that a modulation of synaptic dopamine (DA) levels induced by the inhibition of serotonin (5-HT) release, as a consequence of 5-HT1A agonists administration, might alleviate dyskinesias. Objective Since 5-HT1A receptors are expressed in the subthalamic nucleus (STN), the aim of the present study was to assess the effect of the intrasubthalamic administration of sarizotan, a compound with full 5-HT1A agonist properties, on levodopa-induced dyskinesias in the 6-hydroxydopamine (6-OHDA) model of parkinsonism. Materials and methods Male Sprague–Dawley rats received a unilateral 6-OHDA administration in the nigrostriatal pathway. A test of apomorphine was performed to evaluate dopamine depletion. One week later, a cannula was implanted in the STN. Animals were treated with levodopa (6 mg/kg, i.p., twice at day) for 22 consecutive days. On day 23, several doses (1 ng, 10 ng, or 1 μg) of sarizotan were administered through the cannula to the STN. The higher doses of sarizotan effectively attenuated all levodopa-induced dyskinesias including axial, limb, and orolingual subtypes. Conclusions These results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson’s disease.
- 22 January 2009
- Published by Springer Nature in Psychopharmacology
- Vol. 204 (2) , 241-250
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
Rationale Dyskinesia affects the majority of levodopa-treated parkinsonian patients within 5–10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the appearance of dyskinesias. It is thus conceivable that a modulation of synaptic dopamine (DA) levels induced by the inhibition of serotonin (5-HT) release, as a consequence of 5-HT1A agonists administration, might alleviate dyskinesias. Objective Since 5-HT1A receptors are expressed in the subthalamic nucleus (STN), the aim of the present study was to assess the effect of the intrasubthalamic administration of sarizotan, a compound with full 5-HT1A agonist properties, on levodopa-induced dyskinesias in the 6-hydroxydopamine (6-OHDA) model of parkinsonism. Materials and methods Male Sprague–Dawley rats received a unilateral 6-OHDA administration in the nigrostriatal pathway. A test of apomorphine was performed to evaluate dopamine depletion. One week later, a cannula was implanted in the STN. Animals were treated with levodopa (6 mg/kg, i.p., twice at day) for 22 consecutive days. On day 23, several doses (1 ng, 10 ng, or 1 μg) of sarizotan were administered through the cannula to the STN. The higher doses of sarizotan effectively attenuated all levodopa-induced dyskinesias including axial, limb, and orolingual subtypes. Conclusions These results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson’s disease.
- 1 December 2008
- Published by Elsevier in Neurobiology of Disease
- Vol. 32 (3) , 340-348
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes
- 1 December 2008
- Published by Elsevier in Neurobiology of Disease
- Vol. 32 (3) , 340-348
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes